Kanser Tedavilerine Bağlı Onkolojik Aciller ve Hemşirelik Yönetimi

Yıl 2024, Cilt: 5 Sayı: 1, 45 - 54, 25.10.2024

Akile Karaaslan Eşer

https://doi.org/10.70479/thdd.1405215

Öz

Kanser hastaları tedavi süreci boyunca pek çok kez acil servise başvurmak durumunda kalabilmektedir. Acil servise başvuru nedeni oluşturan ya da acil müdahale gerektiren durumlar onkolojik aciller olarak isimlendirilmektedir. Onkolojik aciller, kanser veya karmaşık tedaviler nedeniyle gelişen, kalıcı hasar ve ölüm riski dolayısıyla hızlı müdahale gerektiren akut durumlardır. Kanserin tanı anından hastalığın son aşamasına kadar herhangi bir dönemde görülebilmektedir. Onkolojik acil durumlar; tümör kaynaklı, metabolik kaynaklı, yapısal kaynaklı ve tedavi kaynaklı olmak üzere farklı şekillerde sınıflandırılabilmektedir. Bu makalede tedaviye bağlı onkolojik acillere yer verilmiştir. Tedaviye bağlı onkolojik aciller kapsamında; ekstravazasyon, sitokin salınım sendromu ve hemorajik sistit konularına ilişkin bilgiler derlenmiştir.

Anahtar Kelimeler

Aciller, kanser, onkoloji hemşireliği

Oncological Emergencies Due to Cancer Treatments and Nursing Management

Öz

Cancer patients visit the emergency room many times during the treatment process. Situations that cause admission to the emergency department or require urgent intervention are called "oncological emergencies". Oncological emergencies are acute situations that develop due to cancer or complex treatments and require rapid intervention due to the risk of permanent damage and death. It can be seen at any time from the moment of diagnosis of cancer to the terminal stage of the disease. Oncological emergencies; It can be classified in different ways, including tumor-related, metabolic-related, structural-related and treatment-related. This article covers treatment-related oncological emergencies. In this article, extravasation, cytokine release syndrome and hemorrhagic cystitis are included within the scope of treatment-related oncological emergencies.

Anahtar Kelimeler

Cancer, emergencies, oncology nursing

Kaynakça

• 1. Kim JT, Park JY, Lee HJ, Cheon YJ. Guidelines for the management of extravasation. J Educ Eval Health Prof. 2020;17:21. doi: 10.3352/jeehp.2020.17.21.
• 2. Can, G. Onkoloji Hemşireliği. 2. Baskı. İstanbul: Nobel Tıp Kitabevi; 2020.
• 3. Kreidieh FY, Moukadem HA, El Saghir NS. Overview, prevention and management of chemotherapy extravasation. World J Clin Oncol. 2016 Feb 10;7(1):87-97. doi: 10.5306/wjco.v7.i1.87.
• 4. Pérez Fidalgo JA, García Fabregat L, Cervantes A, Margulies A, Vidall C, Roila F; ESMO Guidelines Working Group. Management of chemotherapy extravasation: ESMO-EONS Clinical Practice Guidelines. Ann Oncol. 2012 Oct;23 Suppl 7:vii167-73. doi: 10.1093/annonc/mds294.
• 5. Sakaida E, Sekine I, Iwasawa S, Kurimoto R, Uehara T, Ooka Y et al. Incidence, risk factors and treatment outcomes of extravasation of cytotoxic agents in an outpatient chemotherapy clinic. Jpn J Clin Oncol. 2014 Feb;44(2):168-71. doi: 10.1093/jjco/hyt186.
• 6. Marsh N, Webster J, Ullman AJ, Mihala G, Cooke M, Chopra V, et al. Peripheral intravenous catheter non-infectious complications in adults: A systematic review and meta-analysis. J Adv Nurs. 2020 Dec;76(12):3346-3362. doi: 10.1111/jan.14565.
• 7. Wickham R. Vesicant extravasation from an implanted venous access port. Oncology (Williston Park) 2009;23:34-8.
• 8. Schulmeister L. Extravasation management: clinical update. Semin Oncol Nurs. 2011 Feb;27(1):82-90. doi: 10.1016/j.soncn.2010.11.010.
• 9. Wengström Y, Margulies A; European Oncology Nursing Society Task Force. European Oncology Nursing Society extravasation guidelines. Eur J Oncol Nurs. 2008 Sep;12(4):357-61. doi: 10.1016/j.ejon.2008.07.003.
• 10. Breslin S. Cytokine-release syndrome: overview and nursing implications. Clin J Oncol Nurs. 2017 Feb;11(1 Suppl):37-42. 11. Shimabukuro-Vornhagen A, Godel P, Subklewe M, Stemmler HJ, Schlosser HA, Schlaak M, et al. Cytokine release syndrome. J Immunother Cancer;2018; 6(1):56.
• 12. Frey N, Porter D. Cytokine Release Syndrome with Chimeric Antigen Receptor T Cell Therapy. Biol Blood Marrow Transplant; 2019;25:e123.
• 13. National Cancer Institute (2017). Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0. [Erişim tarihi: 20.11.2023]. Erişim adresi: https://ctep.cancer.gov/protocoldevelopment/electronic_applications/docs/ctcae_v5_quick_reference_8.5x11.pdf
• 14. Liem X, Saad F, Delouya G. A Practical Approach to the Management of Radiation-Induced Hemorrhagic Cystitis. Drugs. 2015; Sep;75(13):1471-82.
• 15. Cox JD, Stetz J, Pajak TF. Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European Organization for Research and Treatment of Cancer (EORTC). Int J Radiat Oncol Biol Phys. 1995;31:1341.
• 16. Hensley ML, Hagerty KL, Kewalramani T, Green DM, Meropol NJ, Wasserman TH, et al. American Society of Clinical Oncology 2008 clinical practice guideline update: use of chemotherapy and radiation therapy protectants. J Clin Oncol. 2009; Jan 1;27(1):127-45.